Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas.

Humans Skin Neoplasms / pathology Mycosis Fungoides / pathology Brentuximab Vedotin / therapeutic use Sezary Syndrome / pathology Antineoplastic Agents / therapeutic use Antibodies, Monoclonal / therapeutic use
atezolizumab brentuximab vedotin lacutamab lymphomatoid papulosis mogamulizumab mycosis fungoides nivolumab pembrolizumab primary cutaneous anaplastic large T-cell lymphoma tagraxofusp

Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
20 Nov 2023
Historique:
received: 04 10 2023
revised: 09 11 2023
accepted: 17 11 2023
medline: 27 11 2023
pubmed: 24 11 2023
entrez: 24 11 2023
Statut: epublish

Résumé

In recent years, targeted (biological) therapies have become available also for primary cutaneous T-cell lymphomas (PCTCLs) including anti-CD30 (brentuximab vedotin) in mycosis fungoides, primary cutaneous anaplastic large T-cell lymphoma, lymphomatoid papulosis; anti-CCR4 (mogamulizumab) in Sezary syndrome; anti-CD123 (tagraxofusp) in blastic plasmocytoid cell neoplasm. Moreover, anti-PD1 (nivolumab), anti-PDL1 (pembrolizumab, atezolizumab), anti-CD52 (alemtuzumab), anti-KIR3DL2-CD158k (lacutamab), and anti-CD70 (cusatuzumab) have been tested or are under investigations in phase II trials. The expression of these epitopes on neoplastic cells in skin biopsies or blood samples plays a central role in the management of PCTCL patients. This narrative review aims to provide readers with an update on the latest advances in the newest therapeutic options for PCTCLs.

Identifiants

DOI: 10.3390/cells12222656 PMID: 37998391 PMC: PMC10670482
pubmed: 37998391
pii: cells12222656
doi: 10.3390/cells12222656
pmc: PMC10670482
pii:
doi:

Substances chimiques

Brentuximab Vedotin 7XL5ISS668
Antineoplastic Agents 0
Antibodies, Monoclonal 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Lancet Oncol. 2018 Sep;19(9):1192-1204
pubmed: 30100375
Int J Mol Sci. 2022 Dec 09;23(24):
pubmed: 36555280
J Neurooncol. 2017 May;132(3):439-446
pubmed: 28271282
J Am Acad Dermatol. 2023 Nov;89(5):1044-1047
pubmed: 37321484
J Clin Oncol. 2020 Jan 1;38(1):20-28
pubmed: 31532724
JAMA Dermatol. 2018 Jun 1;154(6):728-730
pubmed: 29800117
Am J Dermatopathol. 2014 Feb;36(2):153-7
pubmed: 24394302
J Cutan Pathol. 2008 Dec;35(12):1100-7
pubmed: 18616762
Hematol Oncol. 2021 Aug;39(3):275-283
pubmed: 33855728
Blood. 2022 Mar 24;139(12):1820-1832
pubmed: 34905599
Dermatology. 2023;239(4):553-564
pubmed: 37231916
Dermatol Ther (Heidelb). 2022 Jan;12(1):29-40
pubmed: 34816383
Leuk Lymphoma. 2009 Dec;50(12):1969-76
pubmed: 19860617
J Eur Acad Dermatol Venereol. 2021 Nov;35(11):2225-2238
pubmed: 34273208
J Eur Acad Dermatol Venereol. 2023 May;37(5):e615-e617
pubmed: 36545932
Ital J Dermatol Venerol. 2022 Aug;157(4):355-362
pubmed: 35373781
Am J Dermatopathol. 2016 Jul;38(7):541-5
pubmed: 26885605
Histopathology. 2020 Jan;76(2):222-232
pubmed: 31355940
Am J Surg Pathol. 1999 Feb;23(2):137-46
pubmed: 9989839
J Clin Oncol. 2016 Aug 10;34(23):2698-704
pubmed: 27269947
Br J Dermatol. 2014 Mar;170(3):720-4
pubmed: 24438061
Eur J Cancer. 2017 May;77:57-74
pubmed: 28365528
J Cutan Pathol. 2008 Jan;35(1):46-53
pubmed: 18095994
Cells. 2023 Jul 27;12(15):
pubmed: 37566023
Future Oncol. 2017 Nov;13(27):2405-2411
pubmed: 28805086
Lancet Oncol. 2019 Aug;20(8):1160-1170
pubmed: 31253572
Eur J Cancer. 2021 Oct;156 Suppl 1:S22-S23
pubmed: 34649647
Haematologica. 2007 Jun;92(6):784-94
pubmed: 17550851
Blood Adv. 2020 Oct 13;4(19):4838-4848
pubmed: 33027528
Am J Surg Pathol. 2004 Jun;28(6):719-35
pubmed: 15166664
Adv Radiat Oncol. 2020 Nov 26;6(3):100629
pubmed: 33748543
JAMA Dermatol. 2014 Jul;150(7):776-9
pubmed: 24760312
Hematol Oncol. 2021 Jun;39 Suppl 1:46-51
pubmed: 34105822
Br J Dermatol. 2021 Jul;185(1):228-230
pubmed: 33480069
Am J Surg Pathol. 2005 Apr;29(4):550-60
pubmed: 15767812
J Eur Acad Dermatol Venereol. 2023 Sep;37(9):1777-1784
pubmed: 37113040
Australas J Dermatol. 2021 May;62(2):e316-e318
pubmed: 32757292
Clin Adv Hematol Oncol. 2023 May;21(5):257-264
pubmed: 37145496
J Biol Regul Homeost Agents. 2001 Jan-Mar;15(1):98-100
pubmed: 11388753
Eur J Haematol. 2003 Oct;71(4):250-6
pubmed: 12950233
Blood. 2019 Apr 18;133(16):1703-1714
pubmed: 30635287
J Eur Acad Dermatol Venereol. 2022 May;36(5):671-679
pubmed: 35080278
Presse Med. 2022 Mar;51(1):104110
pubmed: 35026391
Cancers (Basel). 2022 Mar 25;14(7):
pubmed: 35406431
Leuk Lymphoma. 2021 Dec;62(13):3109-3118
pubmed: 34304674
Am J Surg Pathol. 2010 Jan;34(1):75-87
pubmed: 19956058
Eur J Cancer. 2021 May;148:411-421
pubmed: 33794441
J Invest Dermatol. 2021 Mar;141(3):484-495
pubmed: 33162051
Br J Dermatol. 2022 Aug;187(2):234-243
pubmed: 35194801
Hemasphere. 2023 Feb 21;7(3):e841
pubmed: 36844178
Presse Med. 2022 Mar;51(1):104109
pubmed: 35026390
Am J Surg Pathol. 2009 Dec;33(12):1860-8
pubmed: 19898220
J Clin Oncol. 1998 Oct;16(10):3257-63
pubmed: 9779699
N Engl J Med. 2019 Apr 25;380(17):1628-1637
pubmed: 31018069
J Cutan Pathol. 2023 Aug;50(8):711-716
pubmed: 36944579
Expert Opin Drug Saf. 2019 Sep;18(9):769-776
pubmed: 31303060
J Cutan Pathol. 2008 Oct;35(10):911-5
pubmed: 18494823
Cancer. 2022 Mar 1;128(5):1004-1014
pubmed: 34726773
Ital J Dermatol Venerol. 2021 Aug;156(4):413-421
pubmed: 34037370
Semin Diagn Pathol. 2017 Jan;34(1):22-35
pubmed: 27993440
Br J Dermatol. 2008 Sep;159(4):881-6
pubmed: 18644018
JAMA Dermatol. 2021 Jun 01;157(6):700-707
pubmed: 33881447
Cancer Manag Res. 2022 Nov 22;14:3205-3221
pubmed: 36444356
Br J Dermatol. 2019 Feb;180(2):419-420
pubmed: 30328116
Cells. 2022 Nov 21;11(22):
pubmed: 36429125
Blood Adv. 2021 Dec 14;5(23):5098-5106
pubmed: 34507350
Blood. 2008 Jan 15;111(2):838-45
pubmed: 17934071
Br J Dermatol. 2022 Jan;186(1):153-166
pubmed: 34427917
Presse Med. 2022 Mar;51(1):104126
pubmed: 35569698
Drug Des Devel Ther. 2020 Sep 16;14:3747-3754
pubmed: 32982179
Br J Dermatol. 2020 Jun;182(6):1503-1504
pubmed: 31854457
Blood Cancer J. 2017 Sep 8;7(9):e603
pubmed: 28885612
Dermatology. 2004;208(3):281-3
pubmed: 15118391
J Am Acad Dermatol. 2005 Dec;53(6):1053-63
pubmed: 16310068
Blood. 2023 Feb 16;141(7):695-703
pubmed: 36379025
Am J Dermatopathol. 2014 Dec;36(12):933-48; quiz 949-51
pubmed: 25415138
Clin Lymphoma Myeloma Leuk. 2021 Feb;21(2):97-105
pubmed: 33158772

Auteurs

Benedetta Sonego (B)

Dermatology Clinic, University of Trieste, 35125 Trieste, Italy.
ORCID: 0000-0001-6892-1445

Adalberto Ibatici (A)

UO Ematologia e Terapie Cellulari, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.

Giulia Rivoli (G)

UO Ematologia e Terapie Cellulari, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.

Emanuele Angelucci (E)

UO Ematologia e Terapie Cellulari, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.
ORCID: 0000-0002-6512-6080

Simona Sola (S)

Surgical Pathology, Galliera Hospital, 16128 Genoa, Italy.

Cesare Massone (C)

Dermatology Unit & Scientific Directorate, Galliera Hospital, 16128 Genoa, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Histopathological Markers for Target Therapies...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Tumeurs cutanées › Histopathological Markers for Target Therapies...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Lymphomes › Lymphome malin non hodgkinien › Lymphome T › Lymphome T cutané › Mycosis fongoïde › Histopathological Markers for Target Therapies...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Brentuximab védotine › Histopathological Markers for Target Therapies...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Syndrome de Sézary › Histopathological Markers for Target Therapies...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Histopathological Markers for Target Therapies...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Histopathological Markers for Target Therapies...